Ultime notizie per Astellas Pharma (OTC:ALPMF) Azioni

Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.

Biotech

Large Cap

News

Health Care

General

ALPMF

ALPMY

Nuove prospettive terapeutiche emergono da una ricerca clinica, aprendo orizzonti inattesi nella lotta contro questa aggressiva neoplasia.

Carcinoma uroteliale: studio EV-302 Pfizer/Astellas mostra progressi

ASTELLAS PHARMA INC by Astellas Pharma, Inc.

Comments

Astellas Pharma

Notizie

Ultime notizie per Astellas Pharma (OTC:ALPMF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO